Unlock instant, AI-driven research and patent intelligence for your innovation.

(s)-3-(4-((4-(morpholinylmethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione preparation

A dosing, lubricant technology applied in (S)-3-(4-((4-(morpholinylmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl ) Preparation field of piperidine-2,6-dione

Active Publication Date: 2020-02-14
CELGENE CORP
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Compound A is prone to hydrolysis and has chemical stability issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • (s)-3-(4-((4-(morpholinylmethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione preparation
  • (s)-3-(4-((4-(morpholinylmethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione preparation
  • (s)-3-(4-((4-(morpholinylmethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0286] 5.1 Example 1: Compound A Dosage Capsules

[0287] Table 1 illustrates the batch formulation and single dose formulation of a single dosage unit of Compound A at 0.3 mg strength in #4 capsules.

[0288] Table 1. Formulation of 0.3 mg Strength Compound A Capsules

[0289]

[0290] *Denotes the amount of the salt form of Compound A that provides the potency of 0.3 mg of the free base of Compound A (ie, the amount that provides 0.3 mg of 100% pure Compound A).

[0291] Compound A was premixed with a portion of anhydrous lactose and pregelatinized starch. Pass the premix through a 0.032 inch / 20 mesh screen. Grind the remaining lactose through a 0.032 inch / 20 mesh screen. Combine premix with remaining lactose. To this mixture was further blended stearic acid which passed through a 0.0232 inch / 30 mesh screen. The final blend was enclosed in #4 capsules.

[0292] Table 2 illustrates batch and single dose formulations of single dosage units of 0.1 mg strength Compound...

Embodiment 2

[0307] 5.2 Example 2: Stability of formulations

[0308] The accelerated stability of the 0.3 mg strength PD01-082 formulation (described in Table 1 above) and the other 0.3 mg strength formulations described in Tables 5-7 below were evaluated at 40°C / 75% RH and determined initial , 1-month, 3-month and 6-month time periods impurity levels. To determine impurity levels, the HPLC gradient method was employed using the following conditions:

[0309] Column: XBridge C18 column, 4.6×150mm, 3.5μm particle size

[0310] Temperature: autosampler: ambient temperature; column: 40°C

[0311] Mobile Phase: A: 20mM Ammonium Acetate: Acetonitrile (95:5, v / v)

[0312] B: 20mM ammonium acetate: acetonitrile (10:90, v / v)

[0313]

[0314] Flow rate: 1.0mL / min

[0315] Injection volume: 50μL

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are (S)‑3‑(4‑((4‑(morpholinylmethyl)benzyl)oxy)‑1‑oxoisoindoline‑2‑yl)piperidine‑2,6‑ Pharmaceutical compositions and single unit dosage forms of diketones or pharmaceutically acceptable stereoisomers, prodrugs, salts, solvates, hydrates or clathrates. Also provided are methods of treating, managing or preventing various conditions, such as cancer, inflammatory diseases and / or immune-related conditions.

Description

[0001] This patent application claims priority to U.S. Provisional Patent Application No. 61 / 888,419, filed October 8, 2013, which is incorporated herein by reference in its entirety. [0002] 1. Technical field [0003] Provided herein is (S)-3-(4-((4-(morpholinylmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6- Formulations and dosage forms of diketone or CC-220. Also provided herein are methods of using the formulations and dosage forms. [0004] 2. Background of the invention [0005] Drug substances are usually administered as part of a formulation in combination with one or more other agents that serve different or specialized drug functions. By the selective use of pharmaceutical excipients different types of dosage forms can be prepared. Since pharmaceutical excipients have multiple functions and contribute to pharmaceutical formulations in many different ways, for example, dissolving, diluting, thickening, stabilizing, preserving, coloring, flavoring, etc. Pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/48
CPCA61K9/4858A61K9/4866A61K31/5377A61K47/26Y02A50/30A61P1/04A61P1/16A61P11/06A61P13/08A61P13/12A61P15/00A61P17/00A61P17/14A61P19/02A61P19/08A61P21/02A61P21/04A61P25/00A61P27/16A61P29/00A61P3/00A61P35/00A61P37/00A61P37/02A61P5/14A61P9/14A61K47/14A61K47/36A61K9/0053
Inventor 达尔尚·帕瑞克阿尼尔·门诺
Owner CELGENE CORP